Free Testosterone in Women: Medication-Driven Changes, Normal Ranges, and What Your Lab Result Actually Means

Why Free Testosterone Matters More Than Total Testosterone in Women

Total testosterone includes hormone bound to proteins, primarily sex hormone-binding globulin (SHBG) and albumin. Only the free (unbound) fraction and the loosely albumin-bound fraction can enter cells and activate androgen receptors. In women, because circulating testosterone levels are already 10 to 20 times lower than in men, the free fraction carries disproportionate clinical weight.

Reference ranges published in the Journal of Clinical Endocrinology and Metabolism show that free testosterone in reproductive-age women by equilibrium dialysis spans approximately 0.3 to 1.9 ng/dL (or 10 to 65 pmol/L). These numbers look small. A shift caused by a single medication can move you from the top quartile to below the lower limit of detection, or vice versa, changing symptoms dramatically without the total testosterone moving at all.

The SHBG Multiplier Effect

SHBG is the control dial for free testosterone. When SHBG rises, free testosterone falls even if your ovaries keep producing the same total output. When SHBG drops, free testosterone rises. SHBG is synthesized in the liver and is up-regulated by estrogen and thyroid hormone, and down-regulated by insulin, androgens, and obesity. Any medication that alters hepatic SHBG production therefore changes your free testosterone number without touching your ovaries at all.

Why the Assay Method Is Not Interchangeable

Direct immunoassay for free testosterone performs poorly at low concentrations. A 2008 Endocrine Society position statement concluded that direct free testosterone immunoassays are unreliable in women and children, and the recommendation is to use either equilibrium dialysis (the gold standard) or a calculated value derived from total testosterone, SHBG, and albumin using the Vermeulen formula. When your result comes back, check the assay method. The same blood draw can give you a number two to three times higher on one platform versus another.

How Medications Change Free Testosterone: A Systematic Look

Medications alter free testosterone through three main mechanisms: changing SHBG production, changing total testosterone production at the ovary or adrenal gland, or displacing testosterone from binding proteins. Each mechanism produces a predictable directional change.

Medications That Lower Free Testosterone

Combined oral contraceptives (COCs)

This is the biggest pharmacological suppressor of free testosterone in reproductive-age women. COCs lower free testosterone through two simultaneous mechanisms. The ethinyl estradiol component drives hepatic SHBG production sharply upward. In a randomized crossover study, SHBG levels rose 3- to 4-fold on a 30-mcg ethinyl estradiol pill compared to baseline, and this effect persists for months to years after stopping. Concurrently, progestins with androgenic activity suppress LH, cutting ovarian testosterone output.

The net effect on free testosterone is substantial. One observational study of 124 women found that those on COCs had free testosterone levels roughly 61% lower than non-users, with SHBG being the primary mediating variable. For women who notice low libido, fatigue, or flat mood on the pill, this suppression is a plausible biological contributor rather than a coincidence.

Progestin-only pills using norethindrone have a more modest SHBG effect than ethinyl estradiol-containing formulations, but they are not neutral. Depot medroxyprogesterone acetate (DMPA/Depo-Provera) suppresses LH and reduces ovarian testosterone output with less SHBG elevation than COCs.

Spironolactone

Spironolactone is used for acne, PCOS-related hirsutism, and heart failure. At doses of 50 to 200 mg per day, it blocks androgen receptors directly and also inhibits adrenal androgen synthesis. In a meta-analysis covering PCOS management, spironolactone at 100 mg/day produced a statistically significant reduction in free androgen index compared to placebo. The free testosterone number on your lab report may not fall dramatically by mass, but the receptor-level effect is potent because spironolactone competes with testosterone for receptor binding.

GnRH agonists and antagonists

Leuprolide, nafarelin, and the GnRH antagonists (elagolix, relugolix) suppress pituitary LH and FSH, shutting down ovarian testosterone production. Elagolix at the 200 mg twice-daily dose used for endometriosis reduces estradiol and testosterone into a hypoestrogenic-hypoandrogenic state within weeks. Free testosterone can fall below the assay's lower limit of quantitation. Women on these agents frequently report low libido and fatigue, consistent with androgen suppression.

Statins

Statins reduce hepatic cholesterol synthesis. Because all steroid hormones are cholesterol-derived, there has been concern that statins reduce sex hormone levels. A meta-analysis in the Journal of Sexual Medicine found that statin use was associated with small but significant reductions in total and free testosterone in women. The magnitude is modest compared with COCs or spironolactone, but it is clinically relevant for a woman who is already borderline low.

Corticosteroids

Chronic oral corticosteroid use suppresses the hypothalamic-pituitary-adrenal axis, reducing DHEA-S and adrenal androgen output. Free testosterone falls in proportion to dose and duration. Women on prednisone 10 mg/day or more for more than three months are at measurable risk for androgen depletion in addition to the more well-known risk of bone loss and adrenal suppression.

Medications That Raise Free Testosterone

Exogenous testosterone (TRT and compounded topical T)

This is the most direct pathway. Testosterone prescribed as a cream, gel, or injection adds to the circulating pool of total testosterone, and the free fraction rises in proportion. The Endocrine Society 2019 Clinical Practice Guideline on testosterone therapy in women acknowledges evidence supporting use for hypoactive sexual desire disorder (HSDD) in postmenopausal women, but the guideline also notes the absence of long-term safety data and recommends against doses targeting male physiological ranges.

In clinical practice, topical testosterone formulations are typically dosed to raise free testosterone to mid-to-upper premenopausal female range, not to male ranges. Monitoring involves free testosterone by equilibrium dialysis or calculated method at 3 to 6 weeks after a dose change.

DHEA and prasterone

DHEA is a precursor androgen that converts peripherally to testosterone and estradiol. Oral DHEA 50 mg/day raised free testosterone above premenopausal reference range in postmenopausal women in a randomized trial published in Menopause. Intravaginal prasterone (Intrarosa), FDA-approved for dyspareunia due to GSM, is absorbed locally and produces smaller systemic androgen rises than oral DHEA, but free testosterone monitoring is still reasonable at 3 months for women at the lower or upper limits at baseline.

Insulin-sensitizing agents: metformin and GLP-1 receptor agonists

This is a more nuanced mechanism. In women with PCOS, hyperinsulinemia drives ovarian androgen overproduction and suppresses hepatic SHBG. Reducing insulin resistance with metformin or GLP-1 receptor agonists (semaglutide, liraglutide) lowers insulin, which raises SHBG and can paradoxically lower free testosterone by increasing the bound fraction. However, in some women with PCOS where weight loss substantially reduces ovarian androgen output, free testosterone falls directly. A systematic review in Fertility and Sterility found that metformin reduced free androgen index in women with PCOS by a weighted mean of about 1.6 units compared to placebo.

The net direction of free testosterone change on GLP-1 agonists in PCOS is usually a decrease, driven by weight loss, improved insulin sensitivity, and rising SHBG. This can be clinically helpful for hirsutism and acne.

Certain antiepileptics

Valproic acid is associated with polycystic-appearing ovaries and elevated androgens in women with epilepsy. Studies have found that women on valproate have higher free androgen index than those on lamotrigine or carbamazepine, potentially through insulin-related mechanisms. If you are on valproate and concerned about androgen-excess symptoms, free testosterone monitoring is appropriate.

Thyroid hormone replacement

Hypothyroidism lowers SHBG. Adequate thyroid replacement raises SHBG back toward normal, which lowers free testosterone. Women moving from under-treated to optimally treated hypothyroidism may see a decline in free testosterone even though total testosterone stays stable. This is a physiologically appropriate response, not a deficiency.

Free Testosterone by Life Stage: What Is Normal and What Is Optimal

The concept of "optimal" free testosterone in women is genuinely contested. No large-scale, prospective trial has defined a symptomatic benefit threshold with the rigor of cardiovascular outcome trials. What follows is a clinical framework synthesizing available evidence by life stage.

Reproductive Years (ages 18 to 40)

Free testosterone peaks in the mid-twenties and begins a gradual decline. Data from the Study of Women's Health Across the Nation (SWAN) show that testosterone levels decline in women beginning in the twenties, before the menopausal transition begins. In this life stage, the most common causes of low free testosterone are COC use, functional hypothalamic amenorrhea, and hyperprolactinemia. The most common causes of high free testosterone are PCOS, congenital adrenal hyperplasia, and androgen-secreting tumors (rare).

A reference range by equilibrium dialysis of 0.3 to 1.9 ng/dL applies here, but "optimal" for libido, energy, and body composition has not been established. Clinical judgment requires correlating the number with symptoms.

Trying to Conceive

Free testosterone matters in fertility assessment. Elevated free testosterone in the context of PCOS is associated with anovulation, but the free testosterone number does not directly predict IVF success. The ASRM practice committee notes that androgen excess in PCOS is best characterized by a combination of biochemical and clinical findings rather than a single cutoff. Women pursuing fertility treatment while on testosterone therapy should discontinue it well before conception is attempted, as exogenous testosterone suppresses ovulation.

Pregnancy

Testosterone production rises during pregnancy; SHBG rises even more steeply (5- to 10-fold above baseline), keeping free testosterone low. Exogenous testosterone is contraindicated in pregnancy. Animal data and case reports associate androgen excess in early pregnancy with virilization of female fetuses. Any woman on testosterone therapy who becomes pregnant should stop immediately and contact her prescriber. This is a hard stop, not a dose-reduction situation.

Postpartum and Lactation

Free testosterone is typically suppressed in the lactating period due to elevated prolactin and hypothalamic suppression of GnRH. Low libido and fatigue postpartum therefore have multiple endocrine contributors beyond estrogen alone. Testosterone therapy is not approved for use during lactation. Transfer into breast milk has not been adequately studied, and the developmental effects on a nursing infant are unknown. Caution is warranted.

Perimenopause (typically ages 40 to 52)

Total and free testosterone continue their gradual decline through the menopausal transition. The Menopause Society (NAMS) 2022 Position Statement on Testosterone notes that testosterone levels in perimenopausal women are not consistently lower than in younger women, and that no diagnostic cutoff defines female androgen deficiency syndrome. This means a low number alone does not justify treatment; the number must correlate with symptoms, particularly HSDD.

SHBG often rises during perimenopause as estrogen fluctuates. A woman on oral estrogen therapy (menopausal HRT) will have higher SHBG than one on transdermal estrogen, which means lower free testosterone for the same total testosterone output.

Postmenopause

Ovarian testosterone production falls significantly after menopause. Adrenal androgens become the primary source. Free testosterone declines roughly 50% from peak reproductive-age levels. A randomized trial of transdermal testosterone 300 mcg/day in surgically postmenopausal women (the INTIMATE SM1 study) demonstrated a statistically significant improvement in satisfying sexual events versus placebo. This remains the strongest evidence base for testosterone therapy in women.

Pregnancy, Lactation, and Contraception: The Full Picture

Exogenous testosterone is teratogenic in female fetuses. The FDA has not approved any testosterone product for use in women in the United States, and this applies even more stringently in pregnancy. The 2019 Endocrine Society guideline explicitly recommends that women of reproductive potential use reliable contraception while on testosterone therapy, because the risk to a female fetus is real and the window of virilization risk includes the period before a pregnancy is even recognized.

For women using testosterone therapy for HSDD or androgen insufficiency:

• Use effective non-hormonal contraception or a progestin-only method that does not substantially raise SHBG (e.g., a levonorgestrel IUD). A COC would suppress free testosterone back toward baseline and obscure dose-response.
• Stop testosterone at least one menstrual cycle before attempting conception, and ideally three months before, to allow normalization of ovarian suppression if it has occurred.
• If you discover you are pregnant while on testosterone: stop immediately, inform your obstetric provider, and document the gestational age at last exposure.

During breastfeeding, testosterone therapy should not be used. No adequate human lactation pharmacokinetic study exists for testosterone in nursing women. The potential for androgenic effects on a breastfeeding infant, whose hypothalamic-pituitary axis is immature, justifies this caution.

Who This Is Right For, and Who It Is Not

Women who may benefit from free testosterone measurement

• Premenopausal or postmenopausal women with HSDD and fatigue who have ruled out thyroid disease, depression, and relationship factors
• Women with PCOS being evaluated for androgen excess or monitored on spironolactone
• Women on COCs who want to understand whether pill-driven androgen suppression is contributing to low libido or mood changes
• Women on testosterone therapy who need dose titration
• Women with symptoms of androgen excess (acne, hirsutism, male-pattern hair thinning) where PCOS, congenital adrenal hyperplasia, or an ovarian or adrenal source needs to be ruled out
• Women on chronic corticosteroids, GnRH agonists, or antiepileptics who report new androgen-deficiency symptoms

Women for whom free testosterone measurement adds limited value without context

• Women with no androgen-related symptoms who want general wellness screening (the number without clinical correlation rarely changes management)
• Women using a direct immunoassay platform at low-reference values (the assay noise can exceed the signal)
• Women in the first trimester of pregnancy (physiologically suppressed; not interpretable in that context)

Interpreting Your Result When You Are on a Medication

The single most common interpretive error is reading a free testosterone result without accounting for the SHBG-altering medication the patient is currently taking. Here is a practical approach.

First, note your current medications before the draw. If you are on a COC, your free testosterone will likely be 50 to 60% below what it would be off the pill. A result of 0.4 ng/dL on a COC may represent adequate or even high intrinsic androgen production. The same 0.4 ng/dL off all hormonal medications is a different clinical story.

Second, ask for SHBG to be drawn at the same time as total testosterone. Calculated free testosterone from total T + SHBG + albumin using the Vermeulen formula is recommended by multiple endocrinology societies as superior to direct immunoassay in women.

Third, time the draw consistently. Free testosterone does not follow a strong circadian rhythm in women the way it does in men, but morning draws before 10 a.m. Remain the convention for comparative monitoring.

Fourth, confirm the assay method used and the reference range your laboratory applies. Reference ranges differ substantially between assay platforms, and a result reported as "normal" on one platform might be flagged as low on another.

The Evidence Gap in Women

Women have been under-represented in androgen research. Most reference ranges were established in studies of younger, predominantly white, non-Hispanic women in North America or Europe. The Endocrine Society's 2019 guideline acknowledges that the evidence for testosterone therapy benefits in women is largely restricted to HSDD in postmenopausal women, with limited data in premenopausal women, women with natural menopause, or women from diverse populations. Data on free testosterone in Black women, South Asian women, and women with chronic illness are particularly sparse.

What is directly studied: the suppressive effect of COCs on SHBG and free testosterone; testosterone therapy for HSDD in surgically postmenopausal women; androgen excess in PCOS.

What is extrapolated: optimal free testosterone ranges for energy, bone density, muscle mass, and mood in women; long-term cardiovascular and breast safety of supraphysiological doses.

When your clinician draws free testosterone to evaluate fatigue or cognition in perimenopause, they are working from a plausible physiological rationale but limited direct trial data. That honesty should be part of any shared decision-making conversation.

Monitoring Intervals When a Medication Is Changed

For women starting or changing testosterone therapy: recheck free testosterone (with SHBG and total testosterone) at 6 weeks after each dose change, then every 6 months once stable.

For women starting a COC or stopping one: free testosterone can take 3 to 6 months to restabilize after either initiation or discontinuation, due to the lag in SHBG normalization. One study found SHBG remained significantly elevated at 3 months post-pill cessation in some women. Draw labs no sooner than 3 months after a COC change for the most interpretable result.

For women on spironolactone for PCOS: monitor free testosterone and SHBG at baseline, 3 months, and then annually. The target is symptom resolution, not a specific number.